$MNKD,, $1.45 close. Good news with a new commerci
Post# of 23099
(Total Views: 183)
Posted On: 07/19/2017 7:22:55 AM
$MNKD,, $1.45 close. Good news with a new commercial out. New CFO and Chief Commercial Officer who both have many years experience with good companies. PPS was up $.10 in yesterday's trading (volume of 3 million was light of the 3.7 million daily average). RSI is increasing at 57.77; Slow Stochastic headed in a positive direction; MacD just bottomed out,crossed the signal line and is headed up, the money flow Indicator had been down and is now increasing. It crossed its SMA 10 and EMA 50 and the 200 Simple Moving Average is sitting at $2.49. I am looking for a nice pop of about another $.10 in the next day or two, maybe more if more news hits the streets.
MannKind Corporation (NASDAQ and TASE: MNKD) is a biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. The company dates back to February 1991, when it was incorporated as Pharmaceutical Discovery Corporation (PDC) in Elmsford, New York. Our Technosphere® formulation technology was developed at PDC shortly after its formation. In the mid-1990s, Alfred Mann – at the time, the CEO of MiniMed Inc. – started working with PDC through a collaborative research effort and eventually became a significant shareholder. In 2001, the company merged with two other companies owned by Alfred Mann (CTL Immunotherapies Corp. and Allecure Corp.) and the surviving company changed its name to MannKind Corporation. As a result of this merger, we relocated the corporate headquarters to Valencia, California while focusing the East coast operations – by this time, located in Danbury, Connecticut – on improving the Technosphere® technology and developing our innovative line of delivery devices. Our Danbury location now houses a state-of-the-art manufacturing facility, where we manufacture Afrezza® (insulin human) inhalation powder, our first FDA-approved product. We are currently commercializing Afrezza in the United States, where it is available by prescription from pharmacies nationwide.
MannKind Corporation (NASDAQ and TASE: MNKD) is a biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. The company dates back to February 1991, when it was incorporated as Pharmaceutical Discovery Corporation (PDC) in Elmsford, New York. Our Technosphere® formulation technology was developed at PDC shortly after its formation. In the mid-1990s, Alfred Mann – at the time, the CEO of MiniMed Inc. – started working with PDC through a collaborative research effort and eventually became a significant shareholder. In 2001, the company merged with two other companies owned by Alfred Mann (CTL Immunotherapies Corp. and Allecure Corp.) and the surviving company changed its name to MannKind Corporation. As a result of this merger, we relocated the corporate headquarters to Valencia, California while focusing the East coast operations – by this time, located in Danbury, Connecticut – on improving the Technosphere® technology and developing our innovative line of delivery devices. Our Danbury location now houses a state-of-the-art manufacturing facility, where we manufacture Afrezza® (insulin human) inhalation powder, our first FDA-approved product. We are currently commercializing Afrezza in the United States, where it is available by prescription from pharmacies nationwide.
(0)
(0)
'Everything works out in the end,,,If it hasn't worked out,,it's not the end'
https://twitter.com/twitter/statuses/957208055766241280
https://twitter.com/twitter/statuses/957208055766241280